Project Grant R43GM154591
Award Date
6/1/24
Completion Date
11/30/24
Dollars Obligated
$295K
Federal Agency
National Institute of General Medical Sciences
Awardee
Pearl Bio, Inc. (QRR3ELYYB486)
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
The National Institute of General Medical Sciences (NIGMS) awarded a $218,622 Project Grant to Vitan-Biotech LLC on September 22, 2023 under the Biomedical Research and Research Training program (CFDA 93.859). The grant will fund the development of an integrated pipeline to rapidly discover and characterize selective, high-affinity nanobodies against defined G protein-coupled receptors (GPCRs) that are important for neurological disorders like schizophrenia, pain, Parkinson's, Alzheimer's, and...
The National Science Foundation (NSF) awarded Pearl Bio, Inc., a biotechnology company, a $274,462 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The grant funded the development of a next-generation biomanufacturing platform to engineer new microbial organisms and cellular machinery. This platform enables the incorporation of diverse, non-native components into proteins, creating a new class of biological materials for therapeutic development,...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), provides $303,024 to Biocognon LLC to develop an innovative combinatorial pipeline for discovery of anti-GPCR nanobodies. The funding supports a 3-step process: 1) establishing a robust assembly system for GPCR/nanobody libraries, 2) building a synthetic nanobody library targeting ADRB1 and ADRB2 GPCRs and validating their...
This $240,000 federal Project Grant award under the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop a "plug-and-play platform for the continuous directed evolution of nonribosomal peptide synthetases (NRPS)." The goal is to create a live-cell reporting system that can link NRPS activity and substrate specificity to gene expression, enabling rapid evolution of NRPS enzymes with desired...
The National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) awarded a $349,566 Project Grant to Biosensing Instrument Inc., a for-profit biotech company based in Tempe, Arizona. The funding will support the development of the Spotting-Free Nano-Oscillator Array (SFNOA) technology, an innovative platform for high-throughput, label-free quantification of ligand binding kinetics to transmembrane proteins in their native...
The National Institute of General Medical Sciences (NIGMS) awarded a $350,000 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to Koliber Biosciences Inc. of San Diego, CA. The purpose of this 1-year project is to develop an artificial intelligence-based software platform to facilitate the optimization of peptide-based drug leads. Key product deliverables include: Methods for encoding non-canonical amino acids and cyclic peptides to enable high-performance machine learning...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $295,923 to Avery Digital Data, Inc. to develop precision motion control and DNA fragment joining capabilities for an electronic nanochannel chip device. The goal is to greatly increase the availability of large, synthetic DNA constructs for biomedical researchers by creating a new, automated, and low-cost method of...
The federal Project Grant award for $349,816.00, awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859), aims to develop a prototype instrument, software, and consumable for non-invasive, live-cell identification, tagging, and downstream characterization. The proposed platform will enable live-cell-in, live-cell-out processes to support live cell assays, further cell engineering, and new multiomics discovery...
The National Institute of General Medical Sciences (NIGMS) awarded a $917,454 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Integral Molecular Inc. to develop a novel Membrane Proteome Array (MPA) technology for specificity profiling and de-orphaning of monoclonal antibodies and other biotherapeutics. Integral Molecular, an industry leader in membrane protein antibody discovery and characterization, is leveraging previous SBIR funding to advance the...
The National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) awarded a $986,651 Project Grant (R44GM156258) to Auragent Bioscience LLC (doing business as Brightest Bio), a for-profit manufacturer of goods located in Chesterfield, Missouri. The grant supports the development of an ultrabright fluorescent reagent called a Plasmonic Fluor (PF) to significantly enhance the detection sensitivity of fluorescent Western blot...